Discovery of neo-antigen peptide in the common primary brain tumours

Not Applicable

• Conditions: Health Condition 1: C719- Malignant neoplasm of brain, unspecified

• Registration Number: CTRI/2021/03/032438
• Lead Sponsor: ot Applicable

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Morphology and histology confirmed diffuse gliomas of different WHO grades of II, III and IV, where sufficient tissue will be available for all components of the studies.

2. Karnofsky Performance Status should be more than or equal to 60.

3. Patients should be able to provide written informed consent for the collection and usage of the clinical samples for research purpose.

4. Both primary and recurrent tumors can be collected for research purpose.

Exclusion Criteria

1. Patients, who are not able to provide written consent, should be excluded from the study.

2. Mixed CNS tumors or patients suffering from other cancers should be excluded.

3. Patients suffering from associated viral, bacterial, protozoan and fungal diseases should be excluded.

4. Patients with another neurological disorders/ organ failure should be excluded.

Patients undergoing treatment for diseases other than specified CNS tumors should be excluded.

Study & Design

• Study Type: Observational
• Study Design: Not specified